Uma Krishnamurti, MD, MBBS, PhD
Professor of Pathology and Director of Breast PathologyCards
About
Titles
Professor of Pathology and Director of Breast Pathology
Director of Breast Pathology, Pathology
Biography
Dr. Krishnamurti is a pathologist with expertise in breast pathology, cytopathology, and gynecologic pathology. She completed her residency training in Anatomic and Clinical Pathology at the University of Minnesota and the University of Pittsburgh followed by a Fellowship in Cytopathology at the University of Pittsburgh. She joined the faculty at Yale in 2021, where she is currently Professor of Pathology and Director of Breast Pathology. She has been the primary author of the College of American Pathologists (CAP) gynecologic cancer reporting synoptic templates. She served as Principal Investigator and Director of the Breast Satellite Tissue Bank of Winship Cancer Institute, Emory University, from 2015 to 2021. Her main areas of academic interest include diagnostic, prognostic, and predictive markers of triple-negative and HER2-positive breast cancer.
Dr. Krishnamurti has been a course faculty at the American Society of Cytopathology (ASC), American Society for Clinical Pathology (ASCP), and College of American Pathologists (CAP) annual meetings. She has Chaired the Research and Current Concepts Committee of the ASC and served as a member of the American Joint Commission on Cancer Expert Panel on Protocol for Cancer Staging of the Vulva. Currently, Dr. Krishnamurti serves on the Breast section of the Cancer Committee of the CAP, and on the ASC Bulletin and Cytopath Podcast Committee.
Appointments
Pathology
ProfessorPrimary
Other Departments & Organizations
- All Institutions
- Breast Pathology
- Pathology
- Surgical Pathology
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Fellowship
- University of Pittsburgh (2004)
- Residency
- University of Pittsburgh (2003)
- Residency
- University of Minnesota (2001)
- PhD
- University of Minnesota (1999)
- MD
- University of Delhi (1990)
- MBBS
- University of Delhi (1985)
- MD
- University of Delhi (1984)
Board Certifications
Anatomic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2003
Research
Publications
2026
150 Pathologic Characterization of Non-Mass Enhancement Lesions of the Breast in MRI-Guided Core Biopsies
Jordan T, Liang Y, Krishnamurti U, Lewin J, Zhan H. 150 Pathologic Characterization of Non-Mass Enhancement Lesions of the Breast in MRI-Guided Core Biopsies. Laboratory Investigation 2026, 106: 104429. DOI: 10.1016/j.labinv.2025.104429.Peer-Reviewed Original Research204 Estimating Breast Tumor Size from Histologic Section Involvement: A Correlative Study with Imaging and Gross Pathology
Salehiazar S, Moideen P, Zhan H, Ai D, Krishnamurti U, Liang Y. 204 Estimating Breast Tumor Size from Histologic Section Involvement: A Correlative Study with Imaging and Gross Pathology. Laboratory Investigation 2026, 106: 104483. DOI: 10.1016/j.labinv.2025.104483.Peer-Reviewed Original Research193 Can Histologic Features of Flat Epithelial Atypia Distinguish Cases with and without Co-Existing Ductal Carcinoma In Situ (DCIS)?
Perera N, Zhan H, Ai D, Du J, Krishnamurti U, Liang Y. 193 Can Histologic Features of Flat Epithelial Atypia Distinguish Cases with and without Co-Existing Ductal Carcinoma In Situ (DCIS)? Laboratory Investigation 2026, 106: 104472. DOI: 10.1016/j.labinv.2025.104472.Peer-Reviewed Original Research149 Largest Ductal Diameter as a Histopathologic Predictor of DCIS Extent in Resection Specimens
Jordan T, Liang Y, Krishnamurti U, Zhan H. 149 Largest Ductal Diameter as a Histopathologic Predictor of DCIS Extent in Resection Specimens. Laboratory Investigation 2026, 106: 104428. DOI: 10.1016/j.labinv.2025.104428.Peer-Reviewed Original Research279 Clinical Significance of Endometrial Cells in Papanicolaou Tests of Women Aged 45 or Older: A 3-year Retrospective Histologic Follow-up Study from a Large Institute
Burke O, Zhao J, Adeniran A, Cai G, Krishnamurti U, Sun T. 279 Clinical Significance of Endometrial Cells in Papanicolaou Tests of Women Aged 45 or Older: A 3-year Retrospective Histologic Follow-up Study from a Large Institute. Laboratory Investigation 2026, 106: 104561. DOI: 10.1016/j.labinv.2025.104561.Peer-Reviewed Original ResearchQuantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score.
He M, Chan N, Liu M, Robbins C, Bates K, Benanto J, Colón-Cartagena L, Kahila M, Zhan H, Krishnamurti U, Moutafi M, Yaghoobi V, Liebler D, Fulton R, Rimm D. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Applied Immunohistochemistry & Molecular Morphology 2026 PMID: 41709478, DOI: 10.1097/pai.0000000000001311.Peer-Reviewed Original ResearchTrophoblast cell surface antigen 2Trophoblast cell surface antigen 2 expressionH-scoreBreast cancerQuantitative immunofluorescenceSacituzumab govitecanPathologists' readingsTNBC cohortAntibody-drug conjugate targetsExpression of trophoblast cell surface antigen 2H-score methodSolid tumor typesBreast cancer cohortBreast cancer biopsiesYale-New Haven HospitalBreast cancer samplesCompanion diagnostic testsSurface antigen 2H-score assessmentTumor typesClinical outcomesNew Haven HospitalCancer biopsiesTumor samplesCancer cohort
2025
Prognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute
Wang M, Abi‐Raad R, Adeniran A, Krishnamurti U, Buza N, Hui P, Cai G, Sun T. Prognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute. Cancer Cytopathology 2025, 133: e70057. PMID: 41159755, DOI: 10.1002/cncy.70057.Peer-Reviewed Original ResearchConceptsEarly stage endometrial cancerPW cytologyStage endometrial cancerPelvic washingsAccurate risk stratificationEndometrial cancerPrognostic significancePrognostic impactIndependent predictorsInternational Federation of Gynecology and Obstetrics (FIGO) criteriaStage I/II endometrial cancerAccurate risk stratification of patientsIndependent adverse prognostic factorAssociated with significantly worse disease-free survivalRisk stratification of patientsPelvic washing cytologyRetrospective case-control cohortsMultivariate logistic regression analysisEndometrial cancer stagingAdverse prognostic factorDisease-free survivalInternational FederationTumor histologic subtypeII endometrial cancerEarly stage diseaseInvasive breast carcinoma in a patient with PHTS: a case report
Zhan H, Fischbach N, Lynch M, Liang Y, Krishnamurti U, Cohen P. Invasive breast carcinoma in a patient with PHTS: a case report. Diagnostic Pathology 2025, 20: 120. PMID: 41107919, PMCID: PMC12532417, DOI: 10.1186/s13000-025-01715-1.Peer-Reviewed Original ResearchConceptsPTEN hamartoma tumor syndromeAtypical ductal hyperplasiaHamartoma tumor syndromeTumor syndromeFamily historyBilateral palpable breast massesFocal atypical ductal hyperplasiaFamily history of cancerInvasive breast carcinomaPalpable breast massesEctopic breast tissueBloody nipple dischargeAxillary lymph nodesGermline pathogenic variantsHistory of cancerCase presentationWeInvasive carcinomaBreast carcinomaDuctal hyperplasiaMastectomy specimensNipple dischargeRight breastBenign papillomasMultiple biopsiesPapillary proliferationInterobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study
Korie U, Ai D, Podany P, Zhang H, Zhan H, Kahila M, Colon-Cartagena L, Wei S, Sun H, Du J, Krishnamurti U, Liang Y. Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study. American Journal Of Clinical Pathology 2025, 164: 704-711. PMID: 40994034, DOI: 10.1093/ajcp/aqaf088.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situAtypical ductal hyperplasiaCarcinoma in situSpindle-shaped nucleiAssociated with carcinomaIndividual histologic featuresHistological featuresInterobserver agreementDuctal hyperplasiaBreast pathologistsBiopsy casesCases of atypical ductal hyperplasiaLow-grade ductal carcinoma in situEpithelial cellsClinical follow-up dataLesion extentHistological analysisDiagnostic gray zoneMulti-institutional studyVariable interobserver agreementFollow-up dataModerate to substantial agreementDuct involvementHistologic reviewRadiological findingsEstrogen receptor conversion in bone, liver and lung metastases from breast cancer
Podany P, Zhan H, Ai D, Krishnamurti U, Liang Y. Estrogen receptor conversion in bone, liver and lung metastases from breast cancer. Pathology - Research And Practice 2025, 275: 156222. PMID: 40967162, DOI: 10.1016/j.prp.2025.156222.Peer-Reviewed Original ResearchER conversionPrimary tumorTumor gradeGrade of primary tumorAssociated with worse prognosisMetastasis to boneBreast cancer treatmentMetastatic sitesER-positiveMedian survivalTP53 mutationsLiver metastasesPR positivityPIK3CA mutationsReceptor conversionClinicopathological factorsLung metastasesWorse prognosisNo significant differenceTumor typesBreast cancerGenetic alterationsMetastasisPatient managementTumor
Academic Achievements & Community Involvement
News
News
- March 17, 2026
Yale Pathology Will Have Strong Presence at USCAP 2026
- June 12, 2025
Pathology, Laboratory Medicine Residents, Fellows Feted at Graduation Ceremony
- March 01, 2024
Connecticut Society of Pathologists' Educational Meeting Draws Pathologists from Across the State
- December 19, 2023
Yale Pathologists Lead Effort to Revitalize Connecticut Society of Pathologists